Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment

doi:10.1016/S0149-2918(04)90002-1

Clinical Therapeutics

Volume 26, Issue 1, January 2004, Pages 15-28

https://doi.org/10.1016/S0149-2918(04)90002-1 Get rights and content

Abstract

Background: Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life.

Objective: This article reviews the most current information about the epidemiolog, diagnosis, prevention, and treatment of osteoporosis in men.

Methods: Relevant literature was identified through a search of MEDLINE (1966-June 2003) limited to English-language studies in men. The search terms included fractures, bone density, or osteoporosis plus either epidemiology, diagnosis, prevention, control, or therapy. Additional search terms included specific subtopics (eg, bisphosphonates, calcium, exercise, parathyroid hormone). The authors contributed additional relevant publications.

Results: Morbidity after fragility fracture is at least as high in men as in women, and the rate of fracture-related mortality 1 year hip fracture is approximately double in men compared with women. The bioavailable fraction of testosterone slowly declines into the ninth decade in men. There is evidence that the effect of estrogen on bone is greater than that of testosone in men. Diagnosing osteoporosis in men is complicated by a lack of consensus on how it should be defined. Significant risk factors for osteoporosis or fracture include low bone mineral density, previous fragility fracture, maternal history of fracture, marked hypogonadism, smoking, heavy alcohol intake or alcoholism, low calcium intake, low body mass or body mass index, low physical activity, use of bone-resorbing medication such as glucocorticoids, and the presence of such conditions as hyperthyroidism, hyperparathyroidism, and hypercalciuria. Prevention is paramount and should begin in childhood. During adulthood, calcium (1000–1500 mg/d), vitamin D (400–800 IU/d), and adequate physical activity play crucial preventive roles. When treatment is indicated, the bisphosphonates are the first choice, whereas there is less support for the use of calcitonin or androgen therapy. Parathyroid hormone (1–34) is a promising anabolic therapy. There is also strong evidence for the use of bisphosphonates for the treatment of glucocorticoid-induced osteoporosis.

References (118)

H.A. McKay et al.
Augmented trochanteric bone mineral density after modified physical education classes: A randomized school-based exercise intervention study in prepubescent and early pubescent children
J Pediatr.
(2000)
A. Prentice et al.
Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants
Am J Clin Nutr
(1994)
J.R. Center et al.
Mortality after all major types of osteoporotic fracture in men and women: An observational study
Lancet
(1999)
J.A. Kanis et al.
The components of excess mortality after hip fracture
Bone
(2003)
P. Meunier et al.
Physiological senile involution and pathological rarefraction of bone. Quantitative and comparative histological data
Clin Endocrinol Metab
(1973)
I. Braidman et al.
Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis
Bone
(2000)
M.N. Diaz et al.
The influence of family history of hip fracture on the risk of vertebral deformity in men and women: The European Vertebral Osteoporosis Study
Bone
(1997)
T.P. Van Staa et al.
Utility of medical and drug history in fracture risk prediction among men and women
Bone
(2002)
B. Dawson-Hughes et al.
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
N Engl J Med
(1997)
T.V. Nguyen et al.
Osteoporosis in elderly men and women: Effects of dietary calcium, physical activity, and body mass index
J Bone Miner Res
(2000)

U.M. Kujala et al.

Physical activity and osteoporotic hip fracture risk in men

Arch Intern Med

(2000)

A. Paganini-Hill et al.

Exercise and other factors in the prevention of hip fracture: The Leisure World study

Epidemiology

(1991)

M.E. Nelson et al.

Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial

JAMA

(1994)

E. Orwoll et al.

Alendronate for the treatment of osteoporosis in men

N Engl J Med

(2000)

J.D. Ringe et al.

Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study

J Clin Endocrinol Metab

(2001)

K.G. Saag et al.

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis

N Engl J Med

(1998)

J.D. Adachi et al.

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial

Arthritis Rheum

(2001)

G.P. Trovas et al.

A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis. Effects on bone mineral density and bone markers

J Bone Miner Res

(2002)

E.S. Orwoll et al.

The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis

J Bone Miner Res

(2003)

A.C. Looker et al.

Prevalence of low femoral bone density in older US adults from NHANES III

J Bone Miner Res

(1997)

A. Tenenhouse et al.

Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: The Canadian Multicentre Osteoporosis Study (CaMos)

Osteoporos Int

(2000)

E. Seeman

During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone

Calcif Tissue Int

(2001)

K.M. Davies et al.

Prevalence and severity of vertebral fracture: The Saunders County Bone Quality Study

Osteoporos Int

(1996)

G. Jones et al.

Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES)

Osteoporos Int

(1994)

M. Lunt et al.

Bone density variation and its effect on risk of vertebral deformity in men and women studied in thirteen European centers: The EVOS Study

J Bone Miner Res

(1997)

S.A. Jackson et al.

Vertebral fracture definition from populationbased data: Preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos)

Osteoporos Int

(2000)

T.W. O'Neill et al.

The prevalence of vertebral deformity in European men and women. The European Vertebral Osteoporosis Study

J Bone Miner Res

(1996)

V. Gilsanz et al.

Gender differences in vertebral sizes in adults. Biomechanical implications

Radiology

(1994)

J.D. Adachi et al.

The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada

Osteoporos Int

(2001)

M.E. Mussolino et al.

Risk factors for hip fracture in white men: The NHANES I Epidemiologic Follow-up Study

J Bone Miner Res

(1998)

S.E. Kellie et al.

Sex-specific and race-specific hip fracture rates

Am J Public Health

(1990)

B. Gullberg et al.

World-wide projections for hip fracture

Osteoporos Int

(1997)

E.A. Papadimitropoulos et al.

Current and projected rates of hip fracture in Canada

CMAJ

(1997)

R. Hasserius et al.

Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: A 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study

Osteoporos Int

(2003)

A. Trombetti et al.

Survival and potential years of life lost after hip fracture in men and age-matched women

Osteoporos Int

(2002)

L. Forsen et al.

Survival after hip fracture: Short- and long-term excess mortality according to age and gender

Osteoporos Int

(1999)

S.J. Jacobsen et al.

Race and sex differences in mortality following fracture of the hip

Am J Public Health

(1992)

N.F. Ray et al.

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation

J Bone Miner Res

(1997)

R. Goeree et al.

An assessment of the burden of illness due to osteoporosis in Canada

J Soc Gynaecol Can

(1996)

M.E. Wiktorowicz et al.

Economic implications of hip fracture: Health service use, institutional care and cost in Canada

Osteoporos Int

(2001)

E.S. Orwoll et al.